Expression and Significance of Immune Checkpoints in Clear Cell Carcinoma of the Uterine Cervix

Table 3

Univariate Cox regression analysis of survival among patients with clear cell carcinoma of the uterine cervix ().

Variables	Disease-free survival			Overall survival
	HR	95% CI	value	HR	95% CI	value
Age
<40 years	1.00			1.00
≥40 years	0.67	0.15–2.98	0.596	0.67	0.15–3.00	0.601
Stage
I	1.00			1.00
II	2.81	0.34–23.40	0.340	3.01	0.36–25.10	0.308
Tumour size
<4 cm	1.00			1.00
≥4 cm	4.62	0.89–23.95	0.068	5.67	1.09–29.55	0.039
Parametrial involvement
No	1.00			1.00
Yes	3.88	0.75–20.05	0.106	3.80	0.74–19.64	0.111
LVSI
No	1.00			1.00
Yes	1.20	0.14–9.95	0.869	1.10	0.13–9.17	0.929
Depth of stromal invasion
<1/2	1.00			1.00
≥1/2	0.41	0.08–2.10	0.281	0.42	0.08–2.16	0.299
Lymph node metastasis
No	1.00			1.00
Yes	0.04	0.00–948.3	0.533	0.04	0.00–1492	0.553
B7-H3
Negative	1.00			1.00
Positive	0.04	0.00–179.5	0.447	0.04	0.00–138.9	0.431
B7-H4
Negative	1.00			1.00
Positive	0.35	0.04–2.88	0.326	0.38	0.05–3.20	0.376
PD-L1
Negative	1.00			1.00
Positive	1.40	0.27–7.20	0.691	1.25	0.24–6.44	0.792
VISTA
Negative	1.00			1.00
Positive	1.23	0.24–6.38	0.802	0.82	0.16–4.23	0.812

LVSI: lymphovascular space invasion; PD-L1: programmed cell death-ligand 1; VISTA: V-domain Ig suppressor of T cell activation; HR: hazard ratio; CI: confidence interval.